100 results
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
demonstrated significant progress in transforming the Company’s business model and product portfolio for long-term sustainable growth,” said Denny … , with constant attention to long-term shareholder value. The divestiture of CIMERLI and debt paydown improves our capital structure and sharpens our
8-K
EX-2.1
ryahndb1l2 929gss
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K
EX-99.1
tk81bfccphxek
9 Jan 24
Results of Operations and Financial Condition
9:41pm
8-K
EX-99.1
1obmmax75b 19lmz2
27 Oct 23
Regulation FD Disclosure
4:19pm
424B5
a3ix03k5yfshk21auhh8
12 Sep 23
Prospectus supplement for primary offering
6:04am
424B3
zcn7qvtdpu ks1g0
26 Jul 23
Prospectus supplement
4:59pm
S-4/A
lrc5b5 yzklykxwjuv
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
1zr6zn15pag6rq6sjjx
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
425
dzimukkzy81f55lh
16 Jun 23
Business combination disclosure
5:17pm
425
uie8dt
16 Jun 23
Business combination disclosure
5:16pm
425
6fal67nr80f
16 Jun 23
Business combination disclosure
5:14pm
425
wm0y0mdflu3g
16 Jun 23
Business combination disclosure
5:14pm
425
bi0gz5
16 Jun 23
Business combination disclosure
5:12pm
425
910iz3kew2jcm
16 Jun 23
Business combination disclosure
5:11pm